Truist Financial Corp Castle Biosciences Inc Transaction History
Truist Financial Corp
- $62.9 Billion
- Q3 2024
A detailed history of Truist Financial Corp transactions in Castle Biosciences Inc stock. As of the latest transaction made, Truist Financial Corp holds 20,375 shares of CSTL stock, worth $559,905. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,375
Previous 14,217
43.31%
Holding current value
$559,905
Previous $309,000
88.03%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CSTL
# of Institutions
201Shares Held
24.5MCall Options Held
303KPut Options Held
30.3K-
Black Rock Inc. New York, NY3.04MShares$83.7 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.83MShares$50.2 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.75MShares$48.1 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.26MShares$34.7 Million0.61% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.26MShares$34.5 Million2.85% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $723M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...